[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"wound-closure\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:wound-closure":31},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,54,82,112],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":33,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":42,"lastUpdatePostDateStruct":43,"startDateStruct":46,"completionDateStruct":48,"leadSponsor":50,"locationsCount":53},"100651606","effectiveness-and-costs-of-pressure-ulcer-treatment-and-the-quality-of-life-of-patients-with-pressure-ulcers-receiving-home-based-and-institutional-care-100651606",false,"NCT07763106","Effectiveness and Costs of Pressure Ulcer Treatment and the Quality of Life of Patients With Pressure Ulcers Receiving Home-Based and Institutional Care","Comparative Assessment of the Effectiveness and Costs of Pressure Ulcer Treatment and the Quality of Life of Patients With Pressure Ulcers Receiving Home-Based and Institutional Care","Inclusion Criteria:\n\n* Women and men aged 60 to 90 years,\n* stage II-IV pressure ulcers in the lumbar-sacral area of the trunk, pelvic girdle, and lower limbs,\n* high risk of pressure ulcers (above 15 points on the Waterlow scale),\n* daily functional ability below 40 points on the Barthel scale,\n* consent from the patient or legal guardian\u002Fcaregiver to participate in the study.\n\nExclusion Criteria:\n\n* General contraindications (acute inflammatory conditions and febrile illnesses, venous thrombosis, cachexia),\n* pressure ulcers requiring surgical treatment (black necrosis, inflammation of bones and soft tissues),\n* tunneling pressure ulcers showing signs of acute inflammation,\n* pressure ulcers showing signs of infection (causing fever, swelling, pain, and unpleasant odor),\n* pressure ulcers with a surface area of less than 0.5 cm2,\n* pressure ulcers occurring on the lower legs or feet in patients with acute and chronic venous insufficiency and diabetes,\n* multiple pressure ulcers (\\>2),\n* malignant tumors,\n* decompensated diabetes,\n* end-stage chronic heart failure,\n* end-stage renal disease,\n* mental illness.","ALL","60 Years","90 Years",{"count":20,"type":21},80,"ESTIMATED","INTERVENTIONAL",[24],"NA","A study aimed at comparing the effectiveness of treatment, costs, and quality of life of patients with pressure ulcers in home care and institutional care.\n\nEighty individuals aged 60-90 years with stage II-IV pressure ulcers can participate in the study.\n\nParticipants will be assessed for factors such as health status, independence, mood, and quality of life.\n\nThe study will allow for better tailoring care to patients' needs. Other benefits of participating in the study is that the participants will receive a detailed assessment of their health, nutrition, quality of life, as well as support in managing their pressure ulcers. They will receive regular care and medical evaluations, which may positively impact their health and well-being.\n\nRefusing to participate in this study will not affect the patients treatment in any way.\n\nPlease ask if there is anything that is unclear or if you would like additional information.\n\nTaking part in this study is entirely voluntary.",[27,28,29,30,31,32],"Pressure Ulcer (PU)","Pressure Ulcers, Bedsores, Decubitus Ulcer","Quality of Life","INSTITUTIONAL CARE","Wound Closure","Wound Care",[34,35,36,37,38,39,40],"Pressure Ulcer","Quality of life","Home-Based","Institutional Care","wound care","wound closure","wound treatment","NOT_YET_RECRUITING","2026-08-09",{"date":44,"type":45},"2026-08-13","ACTUAL",{"date":47,"type":21},"2026-09-01",{"date":49,"type":21},"2027-12-31",{"name":51,"class":52},"The Jerzy Kukuczka Academy of Physical Education in Katowice","OTHER",3,{"id":55,"slug":56,"hasResults":11,"nctId":57,"briefTitle":58,"officialTitle":59,"acronym":60,"eligibilityCriteria":61,"healthyVolunteers":11,"sex":16,"minAge":62,"maxAge":4,"enrollmentInfo":63,"targetDuration":4,"studyType":22,"phases":65,"briefSummary":66,"conditions":67,"keywords":68,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":72,"lastUpdatePostDateStruct":73,"startDateStruct":75,"completionDateStruct":77,"leadSponsor":79,"locationsCount":53},"100646029","safety-study-of-microlyte-dualguard-100646029","NCT07695688","Safety Study of Microlyte DualGuard","Feasibility Clinical Trial to Assess the Safety and Potential Effectiveness of Microlyte® DualGuard Wound Dressing on Surgically Created Partial-thickness Donor Site Wounds on Patients Requiring Split- Thickness Skin Grafting; the SAGGA Trial","SAGGA","Inclusion Criteria:\n\n1. Adult patients where creation of a donor site wound for any indication including chronic wound, burn wound, surgical\u002Ftraumatic wound, and tumor excision is indicated.\n2. Thigh donor site wound (DSW) location.\n3. At least 22 years of age.\n4. Ability to understand and provide a signed and dated informed consent form.\n5. Stated willingness to comply with all study procedures and availability for all visits for the duration of the study.\n6. All female subjects of childbearing potential (not surgically sterile or postmenopausal) and male subjects with female partners of childbearing potential must agree to use effective contraception (such as implants, injectables, combined oral contraceptives, intrauterine device, sexual abstinence, vasectomy or vasectomized partner) for the duration of the study (84 days).\n7. Fitzpatrick Skin Type (FST I-VI) assessment and documentation at baseline. Subjects of all FST categories (I-VI) are eligible, and the enrollment strategy will ensure that the full range of FST is represented in the study population (10% minimum enrollment in each FST sub-category).\n\nExclusion Criteria:\n\n1. DSW size of \\> 310 cm2\n2. Calculated glomerular filtration rate (GFR) \\\u003C60 ml\u002Fmin\n3. Hypocalcemia defined as serum corrected calcium of \\\u003C8.0 mg\u002Fdl\n4. Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) \\> 1.5 times the upper limit of normal (ULN).\n5. Serum Creatinine \\> 2.0 mg\u002FdL.\n6. Pregnant, lactating or nursing women.\n7. Unable to provide consent.\n8. Prior adverse reaction or known sensitivity to silver or gallium.\n9. Enrollment in another interventional trial using a systemic therapeutic within 30 days prior to enrollment for this study.\n10. Presumed impairment of wound healing as with prescription drugs or medical diagnoses that have potential to impair wound healing at the discretion of clinical investigator, e.g., cancer, transplant status, autoimmune disease, severe malnutrition, etc.\n11. Any diagnosis with concern for 30-Day mortality.\n12. Any condition that might impair the evaluation of subject safety or that in the investigator opinion would interfere with study requirements.","22 Years",{"count":64,"type":21},53,[24],"The primary purpose of this research is to evaluate the safety and effectiveness of Microlyte® DualGuard wound dressing in the healing of partial thickness donor site wounds, also known as skin graft donor sites. This research will assess wound healing, the occurrence of infection, allergic reaction, pain, and itching while subjects are in the hospital and after discharge. Subjects will complete clinic visits through 12 weeks. This research will also assess the occurrence of donor site wound infection, pain and itching, and scarring at 12 weeks, assessed by subjects using the Patient and Observer Scar Assessment Scale (POSAS).",[31,32],[69,70,71],"Donor site wound","antimicrobial","wound dressing","2026-07-06",{"date":74,"type":45},"2026-07-10",{"date":76,"type":21},"2026-08-30",{"date":78,"type":21},"2027-08",{"name":80,"class":81},"Imbed Biosciences","INDUSTRY",{"id":83,"slug":84,"hasResults":11,"nctId":85,"briefTitle":86,"officialTitle":87,"acronym":4,"eligibilityCriteria":88,"healthyVolunteers":11,"sex":16,"minAge":89,"maxAge":90,"enrollmentInfo":91,"targetDuration":4,"studyType":22,"phases":93,"briefSummary":95,"conditions":96,"keywords":98,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":103,"lastUpdatePostDateStruct":104,"startDateStruct":106,"completionDateStruct":108,"leadSponsor":110,"locationsCount":53},"100617451","phase-2-using-tropocellsr-autologous-platelet-rich-fibrin-prf-to-treat-chronic-non-healing-wounds-100617451","NCT07318792","Using TropoCells(R) Autologous Platelet-Rich Fibrin (PRF) to Treat Chronic Non-Healing Wounds","Evaluation of the Safety and the Clinical Effectiveness of Using Tropocells® Autologous PRF System to Treat Chronic, Non-healing, Non-infected Wounds in Combination With Standard of Care (SOC).","Inclusion Criteria:\n\n* 1\\. Male or female ≥ 18≤ 80 years of age 2. Chronic wounds present for at least thirty (30) days meeting classification as, mild to moderate severity, open exuding wound, including, leg ulcer, pressure ulcer, or mechanically or surgically debrided.\n\n  3\\. Located in any anatomical location on the body. 4. If more than one non-healing wound is present, an index wound will be selected ≥ 1.0 cm2 size and less than or equal to 25.0 cm2.\n\n  5\\. If the wound is in an ulcer cluster the dominant ulcer will be selected, with at least 2.0 cm2 between the index wound and other wounds.\n\n  6\\. The study wound will be present for at least thirty (30) days and the subject will have undergone standard of care assessment and intervention, according to the wound type being evaluated, where SOC may include, but not be limited to, proper cleansing and debridement, off-loading, compression, bioburden reduction, moisture management, infection control, optimized perfusion, venous ablation, nutrition supplementation, smoking cessation counseling and medical therapy, and access to wound and underlying disease education and training.\n\n  7\\. Neurovascular assessment, conducted according to the assessment typically performed for the wound type will be performed during Screening (Study Visit 1), and repeated at the level normally conducted at the follow-up visits. Perfusion should be adequate to sustain a healing process. Neurological examinations will be performed to document the presence of neuropathy and\u002For nerve injury.\n\n  8\\. Documented 40% or less wound closure during thirty (30) days of standard of care (SOC).\n\n  9\\. No clinical signs of infection at the wound site or the affected limb. 10. Post-debridement with no residual necrotic tissue. 11. Platelet counts should be within normal range ≥ 105,000 to \\\u003C450, 000. 12. Hemoglobin (Hgb) ≥ 10 g\u002FdL and Hematocrit (HCT) ≥ 27%. 13. HbA1C ≤ 12%. 14. Chronic renal failure (CRF) and dialysis patients may be enrolled. 15. PT\u002FaPTT\u002FINR should be within normal limits unless the subject is on coumadin, then maintain range of INR 2 to 3.\n\n  16\\. Prealbumin ≥ 15 mg\u002FdL. 17. Adequate off-loading of the wound site for wheelchair bound, bed bound, and ambulatory subjects.\n\n  18\\. Multi-layered compression dressings for venous related wounds. 19. Females of childbearing potential should not be pregnant and agree to avoid conceiving during the study.\n\n  20\\. Males agree to use contraception or abstinence during the study. 21. The subject has provided written informed consent prior to any screening procedures and agrees to comply with study procedures and requirements.\n\n  22\\. Usual care therapies that may be included will be negative pressure wound therapy (NPWT), antimicrobial dressings, collagen containing matrix and packing materials.\n\nExclusion Criteria:\n\n* Exclusion Criteria\n\n  1. Life expectancy is less than twelve (12) months.\n  2. Participation in another clinical trial involving an investigational device or drug within thirty (30) days prior to enrollment.\n  3. Sepsis within two (2) weeks prior to enrollment.\n  4. Soft tissue infection affecting the wound within two (2) weeks prior to enrollment.\n  5. Known osteomyelitis or occult osteomyelitis documented with inflammatory markers ESR ≥ 60 and\u002For CRP ≥7.9 mg\u002FdL.\n  6. Religious constraints to using blood products, including autologous blood.\n  7. Alcohol or substance abuse (other than tobacco) within 2 months prior.\n  8. Severe lymphedema at Stage 3b or greater (lymphostatic elephantiasis).\n  9. The inability to use compression therapy for venous insufficiency or lymphedema.\n  10. Subjects who are cognitively impaired, unable to understand the informed consent, or have a health care proxy.\n  11. Hemophilia, sickle cell anemia, thrombocytopenia, and leukemia or blood dyscrasia.\n  12. History of problems with coagulation, abnormal thrombocytes (platelets), or receiving heparin, intravenously. However, subjects taking coumadin, aspirin, clopidogrel, or other oral anti-coagulants are not excluded.\n  13. Cytostatic therapy within the past 12 months.\n  14. The subject has inadequate venous access for repeated blood draw.\n  15. Known HBV, HCV, or HIV.\n  16. Blood-borne or communicable disease that would likely prevent full participation in the trial (HIV, AIDS, COVID-19).\n  17. Subjects with known sensitivity to blood components of the PRF Kit (e.g., rubber stopper, vacutainer tubing).\n  18. Advanced therapy treatments with hyperbaric oxygen, electrical stimulation (eStim), pulsed electromagnetic energy fields (PEMF), colored light therapies, cellular tissue products (CTPs) like amniotic tissues, Apligraf® and Dermagraft® will be excluded; while NPWT, collagen matrix products (sheet or bulk packing), antimicrobial dressings (surfactants, silver or copper, hypochlorous acid) may be used.\n\nAIDS- acquired immunodeficiency syndrome; COPD-chronic obstructive pulmonary disease; COVID-19- Coronavirus Disease-19; CRP- C-reactive protein; ESR-erythrocyte sedimentation rate; HBV-hepatitis B virus; HCV- hepatitis C virus; HIV- human immune-deficiency virus.","18 Years","80 Years",{"count":92,"type":21},16,[94],"PHASE2","Platelet-based therapies have been used to treat bony and soft tissue effects for more than 30 years. Tropocells® Autologous Platelet-Rich Fibrin (PRF) is being used to treat chronic, non-healing wounds, of a variety of types. This will help determine the safety and effective use of PRF in the treatment of soft tissue defects.",[97,31],"Wound Chronic Draining",[99,100,101,102],"Chronic Non-healing Wounds","TropoCells(R) Platelet-rich Fibrin (PRF)","Autologous Platelet-rich Fibrin (PRF)","Platelet Derived Therapy","2026-01-04",{"date":105,"type":45},"2026-01-06",{"date":107,"type":21},"2026-01-01",{"date":109,"type":21},"2026-12",{"name":111,"class":81},"Estar Medical dba Medical Technologies, LTD",{"id":113,"slug":114,"hasResults":11,"nctId":115,"briefTitle":116,"officialTitle":116,"acronym":4,"eligibilityCriteria":117,"healthyVolunteers":11,"sex":16,"minAge":89,"maxAge":4,"enrollmentInfo":118,"targetDuration":4,"studyType":22,"phases":120,"briefSummary":122,"conditions":123,"keywords":129,"overallStatus":139,"whyStopped":4,"lastUpdateSubmitDate":140,"lastUpdatePostDateStruct":141,"startDateStruct":143,"completionDateStruct":145,"leadSponsor":147,"locationsCount":149},"100610247","phase-4-evaluation-of-the-efficacy-of-stratafix-for-neurosurgical-cranial-and-spine-procedures-100610247","NCT07225101","Evaluation of the Efficacy of STRATAFIX for Neurosurgical Cranial and Spine Procedures","Inclusion Criteria:\n\n* Elective or emergent surgical approaches for cranial or spine neurosurgical approaches, requiring sutures for wound closure, requiring multilayer wound closure\n\nExclusion Criteria:\n\n* Patients with prior surgical wound dehiscence or infection\n* Patients with allergy to suture material",{"count":119,"type":21},160,[121],"PHASE4","This research is studying a device already approved by the Food and Drug Administration (FDA) to treat wound closures. Researchers are studying a large group of people to continue to learn information about the safety of the STRATAFIX suture and how people's bodies react to using it over a long period of time. This research will provide additional information about using STRATAFIX sutures to close surgical wounds.",[31,124,125,126,127,128],"Brain Tumor Adult","Spine","Neurovascular","Hemorrhagic Stroke, Intracerebral","Traumatic Brain Injury",[130,131,132,133,134,135,136,137,138],"Superficial surgical site infection","Suture material","Wound closure techniques","brain tumor","spine","spine trauma","neurosurgery","hemorrhagic stroke","traumatic brain injury","RECRUITING","2025-11-03",{"date":142,"type":45},"2025-11-05",{"date":144,"type":45},"2025-11-01",{"date":146,"type":21},"2026-12-31",{"name":148,"class":52},"University of Michigan",1]